TY - JOUR
T1 - Oligometastatic prostate cancer
T2 - Definitions, clinical outcomes, and treatment considerations
AU - Tosoian, Jeffrey J.
AU - Gorin, Michael A.
AU - Ross, Ashley E.
AU - Pienta, Kenneth J.
AU - Tran, Phuoc T.
AU - Schaeffer, Edward M.
N1 - Funding Information:
A.E.R. is supported by a DOD PRTA award (W81XWH-13-1-0445) as well as a PCF Young Investigator Award and Patrick C. Walsh Investigator Grant. P. T. Tran was funded by the Motta and Nesbitt Families,the DoD (W81XWH-11-1-0272), a Kimmel Translational Science Award (SKF-13-021), an ACS Scholar award (122688-RSG-12-196-01-TBG), the NIH (R01CA166348 and 1U01CA183031) and a Movember-PCF Challenge Award. E.M.S. is supported by NIH U01CA196390-01.
Publisher Copyright:
© 2016 Macmillan Publishers Limited. All rights reserved.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer. Until genomic data exist to provide a biological component to the definition of oligometastatic disease, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies suggest that interventions such as radical prostatectomy and local or metastasis-directed radiotherapy can be performed in the metastatic setting with minimal risk of toxic effects. These therapies seem to decrease the need for subsequent palliative interventions, but insufficient data are available to draw reliable conclusions regarding their effect on survival. Thus, a protocol for clinicians to manage the patient presenting with oligometastatic prostate cancer would be a useful clinical tool.
AB - The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer. Until genomic data exist to provide a biological component to the definition of oligometastatic disease, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies suggest that interventions such as radical prostatectomy and local or metastasis-directed radiotherapy can be performed in the metastatic setting with minimal risk of toxic effects. These therapies seem to decrease the need for subsequent palliative interventions, but insufficient data are available to draw reliable conclusions regarding their effect on survival. Thus, a protocol for clinicians to manage the patient presenting with oligometastatic prostate cancer would be a useful clinical tool.
UR - http://www.scopus.com/inward/record.url?scp=84991030687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991030687&partnerID=8YFLogxK
U2 - 10.1038/nrurol.2016.175
DO - 10.1038/nrurol.2016.175
M3 - Review article
C2 - 27725639
AN - SCOPUS:84991030687
SN - 1759-4812
VL - 14
SP - 15
EP - 25
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 1
ER -